Literature DB >> 12494887

Modulation of human NK cell lines by vascular endothelial growth factor and receptor VEGFR-1 (FLT-1).

Wilson S Chen1, Richard P Kitson, Ronald H Goldfarb.   

Abstract

Our laboratory has previously reported that natural killer (NK) cells bind to angiogenic microvessels in established cancer metastases. Vascular endothelial growth factor (VEGF) plays an important role in solid tumor angiogenesis by enhancing new blood vessel formation to transport nutrients and oxygen into tumors. Here we report that the human natural killer cell lines, NK-92 and YT, express the mRNA message and protein product for VEGF-B and its receptor, VEGFR-1/Flt-1. While stimulation of these cells by the potent angiogenic factor VEGF-A165, which also binds to VEGFR-1, does not alter the proliferation of the cells, it does increase adhesion to a model basement membrane-like extracellular matrix, Matrigel. VEGF-A165 also induces NK cell binding to human microvascular endothelial cells in newly forming but not established microvessels in vitro. These results suggest that human NK cells produce an angiogenic factor which may be involved in autocrine and paracrine regulations of angiogenesis. VEGF-A165 appears to stimulate NK cell adhesion to the microvasculature within established cancer metastases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12494887

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  8 in total

1.  Enhanced natural-killer cell and erythropoietic activities in VEGF-A-overexpressing mice delay F-MuLV-induced erythroleukemia.

Authors:  David Cervi; Yuval Shaked; Mehran Haeri; Tatiana Usenko; Christina R Lee; Jody J Haigh; Andras Nagy; Robert S Kerbel; Eitan Yefenof; Yaacov Ben-David
Journal:  Blood       Date:  2006-10-19       Impact factor: 22.113

2.  The anti-angiogenic activity of IL-12 is increased in iNOS-/- mice and involves NK cells.

Authors:  Aleksandra Bielawska-Pohl; Séverine Blesson; Houssem Benlalam; Aurélie Trenado; Paule Opolon; Olivia Bawa; Valérie Rouffiac; Danuta Dus; Claudine Kieda; Salem Chouaib
Journal:  J Mol Med (Berl)       Date:  2010-04-11       Impact factor: 4.599

3.  A single-nucleotide polymorphism in a half-binding site creates p53 and estrogen receptor control of vascular endothelial growth factor receptor 1.

Authors:  Daniel Menendez; Alberto Inga; Joyce Snipe; Oliver Krysiak; Gilbert Schönfelder; Michael A Resnick
Journal:  Mol Cell Biol       Date:  2007-01-22       Impact factor: 4.272

4.  Immunolocalization and expression of vascular endothelial growth factor receptors (VEGFRs) and neuropilins (NRPs) on keratinocytes in human epidermis.

Authors:  Xiao-Yong Man; Xiao-Hong Yang; Sui-Qing Cai; Yong-Gang Yao; Min Zheng
Journal:  Mol Med       Date:  2006 Jul-Aug       Impact factor: 6.354

5.  Irradiation-induced up-regulation of HLA-E on macrovascular endothelial cells confers protection against killing by activated natural killer cells.

Authors:  Isabelle Riederer; Wolfgang Sievert; Günther Eissner; Michael Molls; Gabriele Multhoff
Journal:  PLoS One       Date:  2010-12-16       Impact factor: 3.240

6.  The relative contributions of each subset of ocular infiltrated cells in experimental choroidal neovascularisation.

Authors:  C Tsutsumi-Miyahara; K-H Sonoda; K Egashira; M Ishibashi; H Qiao; T Oshima; T Murata; M Miyazaki; I F Charo; S Hamano; T Ishibashi
Journal:  Br J Ophthalmol       Date:  2004-09       Impact factor: 4.638

Review 7.  The role of VEGF receptors in angiogenesis; complex partnerships.

Authors:  S Cébe-Suarez; A Zehnder-Fjällman; K Ballmer-Hofer
Journal:  Cell Mol Life Sci       Date:  2006-03       Impact factor: 9.261

8.  Genetic manipulation of primary human natural killer cells to investigate the functional and oncogenic roles of PRDM1.

Authors:  Gehong Dong; Yuping Li; Logan Lee; Xuxiang Liu; Yunfei Shi; Xiaoqian Liu; Alyssa Bouska; Qiang Gong; Lingbo Kong; Jinhui Wang; Chih-Hong Lou; Timothy W McKeithan; Javeed Iqbal; Wing C Chan
Journal:  Haematologica       Date:  2021-09-01       Impact factor: 9.941

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.